Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
about
B7-H5 costimulates human T cells via CD28HImmunotherapy in the treatment of non-small cell lung cancer4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityImmunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatinCutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse modelsControl of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cellsAnti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.Interleukin-6 induces Gr-1+CD11b+ myeloid cells to suppress CD8+ T cell-mediated liver injury in miceSoluble CD27-pool in humans may contribute to T cell activation and tumor immunity.4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccinesTargeting CD137 enhances the efficacy of cetuximab.Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T CellsProtEx technology for the generation of novel therapeutic cancer vaccinesMultifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsSA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell toleranceTumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapyDendritic-cell-based therapeutic cancer vaccinesTargeting CD8+ T-cell tolerance for cancer immunotherapy.Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis.CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.Replicase-based plasmid DNA shows anti-tumor activity.Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease.Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease.CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotypeUsing antibodies in tumour immunotherapy.B7-H1-targeted immunotherapy for head and neck cancer.Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent.Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patientsAdjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.
P2860
Q24295841-67C7C13D-B787-491C-A025-53E7972A51A0Q27000382-C041EDA7-E2D6-4EBB-9F99-30D5289DD2FEQ27012963-AD9D9E44-FF71-47A5-BEC0-DC45B670A511Q27027633-F27F92E5-CAD9-4958-8CEB-E73FC037543AQ28537820-37740223-EB83-4785-A122-8DADED584D78Q28592282-5F0E33C5-F940-46CF-AE27-22D33336AA8CQ30430481-975B4533-5A67-46BF-9211-4DE244EA3979Q30873726-ECB265A2-2D12-4A31-A890-797B726A5F72Q33426409-ED4C2CCC-6A75-40A9-A8E3-0CB38100B356Q33586493-1D3906CA-E32E-4426-9D2F-FEB62D36F879Q33722711-6175D59F-EE92-4AD5-A130-2B9A3CCEBB11Q33730129-5F7FC01B-A25C-43F1-A845-5836301E25A8Q33843364-195BD33C-BEB9-4E10-AD91-FE63B2AE7C44Q33855420-2BD661D0-D254-4975-AAE4-54E1C31F2702Q33857971-15C6A4D5-327A-4AED-9F0F-D32CD9E37B20Q33872482-F2E155A8-598B-4CE6-AC4F-BCA7B84626C2Q33887448-972581F8-A3B3-4921-9E9C-FB384F7853C6Q33900380-397FD2AF-4696-46B2-9C01-12792C231837Q34048819-90F08E23-F859-4F08-AA93-DECE339CDA73Q34052580-EE2BCC3C-8CDD-4E26-91C0-2E1D85BC4B3BQ34065110-BF63035C-43D2-4E15-839E-A92351638A2DQ34122678-E6E1EC8B-5F67-4F5B-A958-102B3A616F0EQ34137777-DDB8B57E-F97C-4463-93E4-BFC25F89AA94Q34180031-337E7972-6179-4FD4-B7F3-E034D7D350EDQ34360094-877F7EE5-1574-49EF-98F1-5AAB133345DFQ34432692-75B9A312-CB86-4724-9D99-C2E7D56C852FQ34468358-49CF7273-D632-4896-B862-949A817330EBQ34707604-4CBB4D58-1BDC-4B20-B84D-06A857E73ACEQ34707621-0C082BB7-1AFA-4EBB-81C0-4FDF6E9E48B9Q34778611-FD3000F7-559B-447E-92E4-4F33483B0BE6Q35051306-F50CE1F9-212E-4A9C-91FA-4E15D932F308Q35144042-DEA788B6-605A-427F-999B-32A1B0AAAFE0Q35780315-66901801-AD2A-43D5-BB22-A6ECDB8A2761Q35804422-B1AA660F-E6B0-4302-83F0-5B5F2201B104Q35828831-C5E9398B-5B23-499A-B03A-798829657C5BQ35842612-EAAE2DE1-D8B0-4F9C-8EAF-4CEAE8C4EBD1Q35907010-59BA8585-6F52-4409-84D8-636A43D79E9EQ35987596-2B0A7E27-A237-424E-AA86-D81928852155Q36057487-9D45F822-25A7-4E04-A4B4-9B4594785E9EQ36174218-AD2DD809-EC68-41F7-8FF4-08B3ED0A4792
P2860
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@ast
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@en
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@nl
type
label
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@ast
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@en
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@nl
prefLabel
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@ast
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@en
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@nl
P2093
P2860
P356
P1476
Provision of antigen and CD137 ...... of poorly immunogenic tumors.
@en
P2093
Aaron J Johnson
Andrei I Chapoval
Dallas B Flies
Gefeng Zhu
Koji Tamada
Larry R Pease
Lieping Chen
Ryan A Wilcox
Scott E Strome
P2860
P304
P356
10.1172/JCI0214184
P407
P577
2002-03-01T00:00:00Z